1. ALLA AKTIER
  2. NYHETER
  3. CHORDATE MEDICAL

Chordate Medical

Nyheter Chordate Medical Nyheter alla bolag
Hej Visste du att du med vår premiumtjänst får fullständig historik i alla grafer, pressmeddelanden och andra notiser för dina favoritbolag direkt som DM i Discord samt en del andra godsaker? Du slipper dessutom störande annonser på sajten. Testa gratis i 14 dagar!

Chordate Medical presents interim report for Q3 2022

Chordate Medical Holding AB (publ) ("Chordate") (Nasdaq First North Stockholm: CMH) will publish its interim report for Q3 2022 on Friday November 18, 2022, at 08:30 am.

A webcast teleconference with CEO Anders Weilandt will be broadcast live on Friday November 18 at 02:00 pm. The conference will be followed by a Q&A session. The presentation will be held in Swedish. It is possible to follow the conference via computer or mobile devices.

To register for the web conference, please follow this link:

https://attendee.gotowebinar.com/register/1081159006671885835

Places are limited so we recommend registering well in advance to secure a place.

A recording of the web conference will be available on the company's website www.chordate.com and on Västra Hamnen Corporate Finance YouTube channel after the conference has ended.

For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in the Nordics, Germany, the UK, Israel, and Saudi Arabia. Chordate Medical's share is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com/en/

Chordate's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Attachments
Chordate Medical presents interim report for Q3 2022

Datum 2022-11-15, kl 17:02
Källa MFN
Bifogade filer
Chordate Medical presents interim report for Q3 2022